SAVACassava Sciences, Inc.

$116M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$19M

Operating Income

-$23M

Net Income

-$21M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$152M

Total Liabilities

$14M

Stockholders' Equity

$137M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$19M	-$18M	-6.1%
Operating Income	-$23M	-$21M	-8.8%
Net Income	-$21M	-$19M	-9.3%

SAVA Q4 2023 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena